DAFNA Capital Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

DAFNA Capital Management’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-28,333	Closed	-$1.59M	–	91
2019 Q1	$1.59M	Hold	28,333	–	–	0.69%	43
2018 Q4	$1.36M	Sell	28,333 -2,823	-9%	-$155K	0.68%	38
2018 Q3	$2.26M	Hold	31,156	–	–	0.93%	36
2018 Q2	$2.57M	Sell	31,156 -2,111	-6%	-$204K	1.2%	25
2018 Q1	$3.49M	Hold	33,267	–	–	1.7%	22
2017 Q4	$4.26M	Buy	+33,267	New	+$4.09M	2.29%	14

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

DAFNA Capital Management's VBIV Position: Q2 2019 in Review

DAFNA Capital Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2019, closing a stake of 28,333 shares — an estimated $1.59M sold.

DAFNA Capital Management first reported a position in VBIV in Q4 2017 and held it in 6 quarters. The position peaked at $4.26M in Q4 2017. 56 funds tracked by Wall St. Rank hold VBIV as of Q2 2019.

DAFNA Capital Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2019 after selling out during the quarter.
DAFNA Capital Management sold 28,333 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2019, an estimated $1.59M.
DAFNA Capital Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2017 and held it in 6 quarters.
DAFNA Capital Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $4.26M in Q4 2017.
56 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2019.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.